1. Academic Validation
  2. Selective, Non-nucleotidic Radiotracer for P2Y12 Receptors: Design, Synthesis, Characterization, and Imaging of Brain Slices

Selective, Non-nucleotidic Radiotracer for P2Y12 Receptors: Design, Synthesis, Characterization, and Imaging of Brain Slices

  • J Med Chem. 2025 Jun 12;68(11):11279-11298. doi: 10.1021/acs.jmedchem.5c00213.
Haneen Al-Hroub 1 Hashem Ali M Al Musawi 1 Aliaa Abdelrahman 1 Vigneshwaran Namasivayam 1 Margot Corbel 2 Fanny Petit 2 Gunes Aksiyote 2 Fabrice Beau 2 Caroline Jan 2 Alexis-Pierre Bemelmans 2 Nadja Van Camp 2 Marie-Anne Peyronneau 3 Alexandra Winkeler 3 Christa E Müller 1
Affiliations

Affiliations

  • 1 PharmaCenter Bonn, Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, Bonn 53121, Germany.
  • 2 Laboratoire des Maladies Neurodégénératives, CEA, CNRS, MIRCen, Université Paris-Saclay, Fontenay-aux-Roses 92265, France.
  • 3 Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), CEA, CNRS, Inserm, Université Paris-Saclay, Orsay 91401, France.
Abstract

The G protein-coupled, ADP-activated P2Y12 receptor (P2Y12R) expressed by microglial cells is involved in neuroinflammation constituting a promising biomarker. Here, we designed and characterized a potent and selective non-nucleotidic P2Y12-antagonist radioligand, [3H]PSB-22219 ([3H]18). The unlabeled compound was stable in rat liver microsomes and selective versus Other ADP-activated receptors. [3H]18 displayed high-affinity binding to membrane preparations recombinantly expressing the human P2Y12R (KD = 4.57 nM), showing very low nonspecific binding. Radioligand binding assays were established and employed to characterize P2Y12Rs natively expressed in human platelet (KD = 2.53 nM), rat brain cortex (KD = 5.35 nM), and mouse microglial cell preparations (KD = 269 nM), with microglia showing extraordinarily high P2Y12R expression. Autoradiography studies allowed the visualization of human P2Y12R overexpression in the brain of a humanized rat model. The new radioligand is expected to become a useful pharmacological tool that will contribute to the development of therapeutics and radiodiagnostics targeting brain P2Y12Rs.

Figures
Products